



## Does stroke location predict walk speed response to gait rehabilitation?

Journal:	<i>Human Brain Mapping</i>
Manuscript ID	HBM-15-0456.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Jones, Simon; University of Cambridge, Clinical Neurosciences          Pomeroy, Valerie; University of East Anglia, Acquired Brain Injury Rehabilitation Alliance          Wang, Jasmine; Harvard University, Neurology          Schlaug, Gottfried; Harvard Medical School, Department of Neurology          Marrapu, Siva; Univ of Cambridge, Stroke Research Group, Dept of Neurology, R3 Neurosciences          Geva, Sharon; University College London,          Rowe, Philip; University of Strathclyde, Bioengineering Unit          Chandler, Elizabeth; University of East Anglia, Acquired Brain Injury Rehabilitation Alliance          Kerr, Andrew; University of Strathclyde, Bioengineering Unit          Baron, Jean-Claude; Univ of Cambridge, Stroke Research Group, Dept of Neurology, R3 Neurosciences</p>
Keywords:	MRI, VLSM, cortico-spinal tract, recovery, ambulation

SCHOLARONE™  
Manuscripts



## Does stroke location predict walk speed response to gait rehabilitation?

P. Simon Jones<sup>1</sup>, Valerie M. Pomeroy<sup>2</sup>, Jasmine Wang<sup>3</sup>, Gottfried Schlaug<sup>3</sup>, S. Tulasi Marrapu<sup>1</sup>, Sharon Geva<sup>1</sup>, Philip J. Rowe<sup>4</sup>, Elizabeth Chandler<sup>2</sup>, Andrew Kerr<sup>4</sup>, Jean-Claude Baron<sup>1,5</sup>, for the SWIFT-Cast investigators.

### Affiliations:

1. Stroke Research Group, Dept of Clinical Neurosciences, University of Cambridge, UK
2. Acquired Brain Injury Rehabilitation Alliance, School of Health Sciences, University of East Anglia, Norwich, UK
3. Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, USA.
4. Bioengineering Unit, University of Strathclyde, Glasgow, UK.
5. Inserm U894, Sorbonne Paris Cité, Centre Hospitalier Sainte-Anne, Paris, France

### **Running head: Stroke location and walking rehabilitation**

### **Correspondence:**

Jean-Claude Baron  
INSERM U894  
2 ter rue d'Alésia  
75014 Paris, France  
tel: (33) (0)1 40788626  
fax: (33) (0)1 45807293  
email: jean-claude.baron@inserm.fr

**Word count (main text):** 5,523

**Key words:** MRI; VLSM; cortico-spinal tract; ambulation; recovery.

**Declaration:** None of the authors has a conflict of interest to declare

## Abstract

**Objectives:** Recovery of independent ambulation after stroke is a major goal. However, which rehabilitation regimen best benefits each individual is unknown and decisions are currently made on a subjective basis. Predictors of response to specific therapies would guide the type of therapy most appropriate for each patient. Although lesion topography is a strong predictor of upper limb response, walking involves more distributed functions. Earlier studies that assessed the cortico-spinal tract (CST) were negative, suggesting other structures may be important.

**Experimental design:** The relationship between lesion topography and response of walking speed to standard rehabilitation was assessed in 50 adult-onset patients using both volumetric measurement of CST lesion load and voxel-based lesion-symptom mapping (VLSM) to assess non-CST structures. Two functional mobility scales, the Functional Ambulation Category (FAC) and the Modified Rivermead Mobility Index (MRMI) were also administered. Performance measures were obtained both at entry into the study (3-42 days post-stroke) and at the end of a six-week therapy. Baseline score, age, time since stroke onset and white matter hyperintensities score were included as nuisance covariates in regression models.

**Principal observations:** CST damage independently predicted response to therapy for FAC and MRMI, but not for Walk speed. However, using VLSM the latter was predicted by damage to the putamen, **insula**, external capsule and neighbouring white matter.

**Conclusions:** Walk speed response to rehabilitation was affected by damage involving the putamen and neighbouring structures but not the CST, while the latter has modest but significant impact on everyday functions of general mobility and gait.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

## Introduction

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Around a third of stroke survivors are unable to ambulate 6 months after stroke (Alexander, et al., 2009), contributing a large portion of functional impairment and lost independence. Accordingly, rehabilitation aimed at recovering independent ambulation is an important part of post-stroke therapy, using various techniques that include apparatus-supported therapy such as treadmill exercise, balance activities and orthoses. However, the type of therapy that would best benefit each individual patient remains uncertain, and currently post-stroke therapy decisions are made on a subjective basis. Therefore, predictors of *response to therapy*, i.e., the gain in functional scores between baseline and final assessments, would be of considerable value in the clinical setting as they would point to the type and amount of therapy most effective in each individual. This would in turn maximise the effects of therapy and enhance recovery for each particular lesion type.

Although previous studies have disagreed regarding the role of some clinical variables such as age, lesion volume and white matter small vessel lesion load as predictors of response to standard therapy (Burke, et al., 2014; Cramer, et al., 2007; Dawes, et al., 2008; Dobkin, et al., 2014; Held, et al., 2012; Jorgensen, et al., 1995; Kollen, et al., 2005; Lam, et al., 2010; Lindenberg, et al., 2012; O'Shea, et al., 2014; Stinear, et al., 2007), time since stroke onset has been consistently found to influence, albeit weakly, response to rehabilitation therapy (Kollen, et al., 2005; Lam, et al., 2010; O'Shea, et al., 2014; Stinear, et al., 2007). Another, probably stronger clinical predictor is baseline impairment (Burke, et al., 2014; Cramer, et al., 2007; Dawes, et al., 2008; Dobkin, et al., 2014; Kollen, et al., 2005; Lindenberg, et al., 2012; O'Shea, et al.,

1  
2  
3 2014; Riley, et al., 2011; Stinear, et al., 2007). However, lesion topography is  
4  
5 generally considered the strongest potential predictor of response to therapy after  
6  
7 stroke.  
8  
9

10  
11 Damage to the cortico-spinal tract (CST), and particularly to the portion of the CST  
12  
13 originating from the primary motor cortex (M1), has consistently been reported as a  
14  
15 major determinant of *final outcome*, including global impairment (Pineiro, et al.,  
16  
17 2000; Puig, et al., 2013; Puig, et al., 2011; Puig, et al., 2010) and particularly upper  
18  
19 limb weakness (Feng, et al., 2015; Kim, et al., 2013; Lindenberg, et al., 2010; Lo, et  
20  
21 al., 2010; Maraka, et al., 2014; Qiu, et al., 2011; Rosso, et al., 2013; Schaechter, et al.,  
22  
23 2009; Schulz, et al., 2012; Stinear, et al., 2007; Zhu, et al., 2010). However,  
24  
25 information regarding how lesion topography affects walking outcome is scarce. As  
26  
27 expected based on established CST neuroanatomy, in **three** studies leg weakness was  
28  
29 significantly related to CST damage measured as involvement of the posterior limb of  
30  
31 the internal capsule (PLIC) (Jayaram, et al., 2012; Lee, et al., 2005) or corona radiata  
32  
33 (Alexander, et al., 2009), or overlap of the lesion with the whole extent of the CST  
34  
35 (Jayaram, et al., 2012). However, walking and gait entail considerably more complex  
36  
37 functions than just will-guided leg strength, and consequently are expected to involve  
38  
39 more extensive systems than solely the CST (Perennou and Hillier, 2014).  
40  
41 Accordingly, **neither Jayaram et al nor Dawes et al found a significant**  
42  
43 **relationship between lesion CST overlap and walking speed in the chronic stage**  
44  
45 **post-stroke (Dawes, et al., 2008; Jayaram, et al., 2012). In one study the amount**  
46  
47 **of CST damage predicted ambulation outcome assessed with the Functional**  
48  
49 **ambulation category scale (Kim, et al., 2013), possibly suggesting a differential**  
50  
51 **role of CST damage on walking speed versus actual ambulation.** Interestingly,  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Alexander et al found that damage to the putamen, insula and external capsule was  
4 related to gait asymmetry (Alexander, et al., 2009), while abnormal activation of the  
5 basal ganglia, insula, secondary somatosensory area, or supplementary motor and  
6 premotor cortex during leg movement have also been found associated with impaired  
7 lower limb movement (Dobkin, et al., 2004; Enzinger, et al., 2009; Mihara, et al.,  
8 2012; Miyai, et al., 2003). Overall, therefore, other structures beyond the CST may be  
9 involved in walking impairment after stroke.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 Although as just described there is relatively abundant knowledge regarding the lesion  
21 anatomy of post-stroke motor impairment, particularly for the upper limb, much less  
22 is known of the predictive value of lesion topography for *response to therapy*, **i.e., the**  
23 **change in clinical measures of motor deficit following participation in**  
24 **characterized rehabilitation intervention**. Several studies have consistently  
25 reported that CST damage predicts response of upper limb motor deficit to therapy  
26 (Lindenberg, et al., 2012; Nouri and Cramer, 2011; Riley, et al., 2011; Stinear, et al.,  
27 2007). In those studies, however, a substantial fraction of the variance in response to  
28 therapy remained unexplained, suggesting other systems are also involved. So far, two  
29 studies only have addressed the predictive value of CST damage for walking  
30 recovery. Both showed no significant relationship of CST lesion overlap (Burke, et  
31 al., 2014) (Dawes, et al., 2008), further suggesting that CST is not a strong  
32 determinant of recovery of walking speed, and that other structures are probably  
33 involved.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53  
54 In the present prospective study on a substantial sample of stroke survivors, we used  
55 volumetric CST lesion load measurement (Zhu, et al., 2010) to assess the relationship  
56  
57  
58  
59  
60

1  
2  
3 between CST damage and response of walking speed to ambulation rehabilitation. In  
4  
5 addition to specific CST damage volumetry, we also used voxel-based lesion-  
6  
7 symptom mapping (VLSM) (Bates, et al., 2003) to assess the role of non-CST  
8  
9 structures. Finally, in addition to walk speed, two clinical scales measuring everyday  
10  
11 mobility were also obtained.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

## Subjects and Methods

### Patients

Participants were prospectively recruited in the Soft-Scotch Walking Initial Foot (SWIFT) Cast randomised controlled trial. The trial evaluated the efficacy of augmenting conventional therapy, which could include standard ankle-foot orthoses, with a specific ankle-foot cast (SWIFT Cast) to enhance walking recovery (Pomeroy, et al., 2012). Only those patients who had agreed to undertake MR imaging, which was optional per protocol, were eligible for the present study. As the trial was completely neutral (Pomeroy, et al., 2015), both patient groups were merged for the analysis, as in two previous publications (Burke, et al., 2014; Cramer, et al., 2007).

As detailed elsewhere (Pomeroy, et al., 2012), inclusion criteria were: aged 18+ years; 3-42 days after stroke; infarct or haemorrhage; subjects in whom gait rehabilitation was judged both necessary and potentially useful, namely presence of gait abnormalities (knee hyperextension and/or abnormal initial floor contact) but able to take at least 3 steps while supported by two people; no contractures at hip, knee, ankle or forefoot or loss of skin integrity over the paretic foot/lower limb; able to follow a 1-stage command i.e. sufficient communication/orientation for interventions in this trial; and otherwise physically fit for rehabilitation. Potentially eligible patients were enrolled into the study as soon as they were able to take at least 3 steps while supported by two people. Nature of the stroke (ie, ischemic or haemorrhagic) and ischemic stroke subtype (ie, large-vessel or lacunar) and topography were not part of

1  
2  
3 the inclusion criteria as the aim of the study was to recruit a sample as representative  
4  
5 of patients referred for gait therapy to a rehabilitation unit as possible.  
6  
7

8  
9  
10 The protocol was approved by the relevant Regional Ethics Committees and  
11  
12 registered on a clinical trials database (ISRCTN 39201286). Each participant gave  
13  
14 signed informed consent.  
15  
16

### 17 18 **Clinical Assessment** 19

20  
21 Functional performance measures were taken at entry into the study and the end of six  
22  
23 weeks of intervention phase (Pomeroy, et al., 2012). The primary outcome measure  
24  
25 was average walking speed ( $\text{m}\cdot\text{s}^{-1}$ ). Walking speed was measured using a two-  
26  
27 dimensional light switch and video system which has good reliability (Ugbolue, et al.,  
28  
29 2013). **Walking speed was chosen as the primary measure for the investigation of**  
30  
31 **clinical efficacy as (a) it has international clinical utility; (b) was the target**  
32  
33 **functional improvement for a SWIFT Cast; (c) is a meaningful functional**  
34  
35 **outcome for stroke survivors; and (d) is used widely in stroke rehabilitation**  
36  
37 **trials.**  
38  
39

40  
41  
42 In addition to walk speed, which is an objective metric for walking ability, two  
43  
44 functional mobility scales that incorporate other factors than just motricity were  
45  
46 obtained as secondary outcomes, namely the Functional Ambulation Category (FAC)  
47  
48 and the Modified Rivermead Mobility Index (MRMI) (Lennon and Johnson, 2000).  
49  
50 The FAC scale has six levels (Holden, et al., 1984) ranging from unable to walk  
51  
52 (score 0) to able to walk independently (score 5), and includes components of balance  
53  
54 and supporting use of the upper limbs for the scores up to 4. This measure has been  
55  
56  
57  
58  
59  
60

1  
2  
3 found to have strong inter-rater and test-retest reliability (Mehrholz, et al., 2007). The  
4  
5 MRMI measures functional mobility across eight tasks including turning over in bed,  
6  
7 sitting up from the lying position, sitting balance, transferring to a chair, sitting to  
8  
9 standing, walking indoors and ascending stairs (Walsh, et al., 2010). Each MRMI task  
10  
11 ranges from ‘unable to perform’ (score 0) to ‘independent’ (score 5). The amount and  
12  
13 content of the physical therapy received by participants is described elsewhere  
14  
15 (Pomeroy, et al., 2015). The mean number of trial-specific rehabilitation sessions per  
16  
17 participant was nine, with each session lasting a mean of 40 (SD 16) minutes over the  
18  
19 six-week intervention phase.  
20  
21  
22  
23  
24

25 Given the aim of the present study to assess the anatomical predictors of response to  
26  
27 therapy, the difference between the baseline and outcome measures for the three  
28  
29 behavioural variables detailed above were calculated and used in all statistical  
30  
31 analyses below, unless indicated otherwise.  
32  
33  
34  
35  
36

### 37 **MR data acquisition**

38 **The imaging substudy was part of the prospective trial design (Pomeroy, et al.,**  
39  
40 **2012), and aimed to address the question Does stroke location predict response to**  
41  
42 **gait rehabilitation?, “predict” being used here in the statistical perspective, not**  
43  
44 **at the individual subject level, ie, is there a location that correlates with response**  
45  
46 **to therapy across the group?** Patients who agreed to undergo scanning underwent  
47  
48 structural MRI including a whole-brain ‘volume’ MPRAGE T1-weighted sequence  
49  
50 and a T2-weighted FLAIR sequence (see below). In order to have an accurate  
51  
52 delineation of the cerebral lesion, this session was undertaken three to eight weeks  
53  
54 after stroke onset so that the lesion had stabilized (Gaudinski, et al., 2008), i.e.  
55  
56  
57  
58  
59  
60

1  
2  
3 without remaining swelling from oedema but before substantial shrinkage develops  
4  
5 (Deoni, et al., 2008; Gale and Pearson, 2012).  
6  
7

8  
9  
10 Scanning was performed at two recruiting centres using similar Siemens 1.5T  
11  
12 scanners (Avanto and Magnetom Sonata, respectively). Whole-brain T1-weighted MR  
13  
14 scans were acquired using a standard magnetization-prepared rapid acquisition  
15  
16 gradient-echo (MPRAGE) sequence, which was followed by a standard whole-brain  
17  
18 T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence with 4 mm thick  
19  
20 slices and 1 mm inter-slice gap.  
21  
22

### 23 24 25 **Lesion delineation**

26  
27 Using MRICron ([www.cabiatl.com/mricron/index.html](http://www.cabiatl.com/mricron/index.html)), the stroke lesion was  
28  
29 delineated on FLAIR images (with help from the T1-MPRAGE images whenever  
30  
31 appropriate) by a stroke neurologist with imaging experience (J-CB), blinded to all  
32  
33 clinical data except the side of the stroke. In addition, white matter hyperintense  
34  
35 lesions on FLAIR were rated according to the standard Fazekas scale, from 0 (absent)  
36  
37 to 3 (maximum) (Fazekas, 1989).  
38  
39  
40  
41  
42

### 43 44 **Image processing**

45  
46 All image processing was performed in SPM8 (Wellcome Trust Centre for  
47  
48 Neuroimaging, <http://www.fil.ion.ucl.ac.uk/spm/software/spm8>). The FLAIR images  
49  
50 were coregistered to the T1 images and the T1 images were resliced to the FLAIR  
51  
52 space. The lesions were smoothed using the SPM masking option of MRICron  
53  
54 (Rorden, et al., 2007) (<http://www.cabiatl.com/mricron/mricron/mricron.html>). T1 images  
55  
56 were transformed into Montreal Neurological Institute (MNI) space using the unified  
57  
58  
59  
60

1  
2  
3 Segmentation and Warping process with lesion cost function masking (Andersen, et  
4 al., 2010; Brett, et al., 2001) and the transformation parameters were applied to the  
5 original lesions using nearest-neighbour interpolation to place the lesions in standard  
6 space.  
7  
8  
9

10  
11  
12  
13  
14 For the analyses described below, all right-sided lesions were flipped onto the left  
15 hemisphere to permit comparison across the whole group.  
16  
17  
18

### 19 20 21 **Corticospinal tract (CST) lesion load**

22  
23 The aim of this analysis was to assess the relationship between the amount of damage  
24 to the CST and the clinical measures across the patient sample. For each subject the  
25 probabilistic volume overlap of their lesion with the CST was computed according to  
26 the weighted-CST lesion load (wCST-LL) method (Zhu, et al., 2010). The wCST-LL  
27 was calculated by weighing each slice of overlap with the CST by the ratio of the  
28 maximum cross-sectional area of the CST over the cross-sectional area of that specific  
29 slice. This weighing option corrects for the narrowing of the CST descending into the  
30 PLIC from the motor cortex. In contrast to Zhu et al (2010), the canonical CST tract  
31 used in this study was determined by a probabilistic fiber tracing approach using FSL  
32 3.1.2 (<http://www.fmrib.ox.ac.uk>) and DTI data from 12 healthy elderly control  
33 subjects (9 male; mean age:  $56.5 \pm 14.8$  years) (Feng, et al., 2015). Preprocessing  
34 steps included correction for eddy current effects, skull stripping as well as estimation  
35 and fitting of diffusion parameters. Single slice regions of interest (ROIs) were drawn  
36 on the FA images in the pons, PLIC, and the white matter underlying the posterior  
37 part of the precentral gyrus. Exclusion ROIs were drawn on the superior and medial  
38 cerebellar peduncle to exclude fibres to the cerebellum, as well as the middle sagittal  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 region covering the brain stem and corpus callosum to exclude trans-hemispheric  
4  
5 fibers. Probtrackx ([http://www.fmrib.ox.ac.uk/fsl/fdt/fdt\\_probtrackx.html](http://www.fmrib.ox.ac.uk/fsl/fdt/fdt_probtrackx.html)) was used  
6  
7 to track fibers from the pons ROI as the seeding region. Tracts were normalized to the  
8  
9 SPM5 T2 template implemented in MATLAB (The Mathworks, Inc., Natick, MA),  
10  
11 which was achieved by normalizing the DWI image to the SPM 5 T2 template, and  
12  
13 then applying the normalization parameter to each CST tract. A 50<sup>th</sup> fractional  
14  
15 anisotropy percentile threshold was applied to each CST fiber, and then the twelve  
16  
17 tracts were each binarized and summed to create the canonical CST. wCST-LL values  
18  
19 obtained using this canonical CST significantly ( $p < 0.0001$ ) predicted 3-month Fugl-  
20  
21 Meyer (FM) (Fugl-Meyer, et al., 1975) **upper** extremity sensorimotor outcome in an  
22  
23 unrelated dataset of 76 subjects (Feng, et al., 2015). **Supplemental figure 1** illustrates  
24  
25 the excellent coverage of motor fibers originating from the M1 leg area.  
26  
27  
28  
29  
30  
31

## 32 VLSM

33  
34 VLSM was performed using vlsm2 version 2.53 (Bates, et al., 2003)  
35  
36 (<http://www.neuroling.arizona.edu/resources.html>). Each VLSM analysis identified  
37  
38 clusters of voxels with statistically significant t-values comparing voxelwise subjects'  
39  
40 clinical measures with lesions to those without lesions, and identified a peak t-value  
41  
42 within each significant cluster. Note that to avoid spurious results due to low numbers  
43  
44 of lesioned voxels, only voxels lesioned in at least 6 participants were tested. **The**  
45  
46 **VLSM analysis involved first creating a t-value map showing voxels with**  
47  
48 **greatest difference in responses to lesioned and unlesioned status, thresholded at**  
49  
50 **an uncorrected default cut-off of  $p < 0.005$ . In the second step, the confidence in**  
51  
52 **this cluster was tested by permuting the subject data 5000 times, giving a**  
53  
54 **distribution of clusters with a range of peak t-values. A cluster observed with the**  
55  
56  
57  
58  
59  
60

1  
2  
3 first step was deemed significant at the  $p < 0.05$  level if its t-value was in the top  
4  
5 5% of the clusters produced from randomly permuted data. The initial default  
6  
7 cluster-forming threshold used was  $p < 0.005$ . To correct for multiple comparisons the  
8  
9 significance of the cluster was found by randomly permuting the measures 5,000  
10  
11 times between subjects, i.e., non-parametrically. Only clusters with a peak t-values in  
12  
13 the top 5% of those generated randomly were considered significant ( $p < 0.05$ ,  
14  
15 permutation corrected).  
16  
17

18  
19  
20 In order to determine as objectively as possible the anatomical structures involved by  
21  
22 the significant clusters, the location of each cluster was labelled according to the  
23  
24 Hammers atlas (Hammers, et al., 2003; Heckemann, et al., 2006) ([www.brain-](http://www.brain-development.org)  
25  
26 [development.org](http://www.brain-development.org)) for grey matter structures, the John Hopkins University (JHU)  
27  
28 white-matter tracts atlas (Hua, et al., 2008), and where possible the Anatomy  
29  
30 (Eickhoff, et al., 2005) atlas for Brodmann's areas (BAs). We used the JHU tract atlas  
31  
32 to assess the overlap of VLSM clusters with white matter tracts, including the CST.  
33  
34 For each label, the percentage of the cluster overlapping with the given  
35  
36 structure/tract/BA was obtained and tabulated.  
37  
38  
39  
40  
41  
42

### 43 **Statistical Analysis**

44  
45 *Clinical data:* Descriptive statistics were used to present the clinical data and their  
46  
47 inter-relationships. Continuous measures were summarized by mean and standard  
48  
49 deviation or 95% Confidence Interval, and categorical data by median with  
50  
51 interquartile range. Correlations were made using Kendall's Tau; corrections for  
52  
53 multiple tests were deemed unnecessary given the descriptive aim. Statistical analyses  
54  
55 were performed in SPSS 21 (IBM SPSS Statistics for Windows, Version 21.0).  
56  
57  
58  
59  
60

1  
2  
3 Armonk, NY: IBM Corp). **Because a relatively large sample was used in this**  
4  
5 **study, interpretation of the findings from correlations was not based only on the**  
6  
7 **p value, which indicates the presence of a statistically significant relationship,**  
8  
9 **but also on the r value, which assesses the strength of the relationship. In the**  
10  
11 **present study we considered  $\tau \geq 0.6$  to represent a strong relationship.**

12  
13  
14  
15  
16  
17  
18 *wCST-LL analysis*: the analysis of the relationship between wCST\_LL and response  
19  
20 to therapy for each of the three clinical scales was carried out with age, Fazekas score,  
21  
22 time from stroke onset to baseline performance measures (to be referred to as “Time”  
23  
24 below), and baseline score for the considered variable as added nuisance covariates.  
25  
26 Lesion volume was not included as covariate as this can cause spurious results given  
27  
28 the relationship between stroke size and topography according to vascular territories  
29  
30 (Nachev, 2014). In addition, there was not even a trend of a correlation between  
31  
32 lesion volume and response to therapy for any of the three clinical variables assessed  
33  
34 (r range: 0.01-0.06, all  $p > 0.53$ ; data not shown). **Multiple regressions were carried**  
35  
36 **out for Walk speed and MRMI which are continuous and multiple categories**  
37  
38 **variables, respectively, while for FAC, which has only five categories, ordinal**  
39  
40 **regression was carried out.**

41  
42  
43  
44  
45  
46  
47 *VLSM*: As with wCST-LL, all four covariates described above were added in the  
48  
49 VLSM analysis for each of the three variables.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

### Patient characteristics and behavioural scores

Of the 105 trial participants, 56 consented to MR imaging but 4 were not suitable for inclusion in the image analysis (one had a hemi-craniectomy and another had marked hydrocephalus entailing marked brain distortion, one declined study approval after the MR session, and one had no visible lesion on MR), leaving 52 subjects with adequate MRI for the present study. **Due to practical difficulties in obtaining MR slots for this research, some scans were carried out slightly later than expected (mean time of MR relative to stroke onset: 52 days; range 17-74 days), even sometimes a few days after end of therapy. Because outcome clinical scores were not available in two additional patients, the final analysis was on 50 subjects.**

**Table 1** shows the patient demographics. The median time from stroke to enrolment in the trial was **16** days (range: 3-42 days), and for performance of MRI 52.9 days (SD: 11.8). This subset of **50** subjects did not significantly differ from the remaining 53 trial subjects in any demographic or baseline clinical measure (data not shown). This material was made of 41 ischemic and 9 haemorrhagic strokes, of which 4 were hemispheric, 4 supratentorial deep-seated and one involved the brain-stem. Of the ischemic strokes, 22 were MCA-territory strokes (eight of which were purely deep-seated and two associated with posterior cerebral artery infarction), two were anterior cerebral artery (ACA) strokes, one was an anterior choroidal artery stroke, and 16 were lacunar infarcts (three of which located in the brainstem).

1  
2  
3 **Table 2** shows the functional scores of the participants at baseline and six-week  
4  
5 outcome, and the change from baseline to outcome. There was improved performance  
6  
7 following treatment in all three functional measures, with average Walk Speed  
8  
9 improving by  $0.31\text{m}\cdot\text{s}^{-1}$  ( $p<0.0001$ ), MRMI by 10.06 ( $p<0.0001$ ) and FAC by 2.42  
10  
11 ( $p<0.0001$ ).  
12

13  
14  
15  
16 There were significant positive correlations regarding change in scores among all  
17  
18 three clinical measures (all  $p<0.03$ ), **particularly between FAC and MRMI**  
19  
20 ( $p<0.001$ ). However, **they were weak between Walk speed and the other two**  
21  
22 **scales (highest tau value: 0.386)**, while the tau value between MRMI and FAC was  
23  
24 0.611, indicating that a large part of the variance remained unexplained. Accordingly,  
25  
26 the wCST-LL and VLSM analyses were conducted for each variable separately,  
27  
28 **which also was justified by the marked differences in the everyday functions they**  
29  
30 **assess (see Discussion).**  
31  
32

33  
34  
35  
36 **Table 3** shows the correlations of response to therapy for each behavioural measure  
37  
38 with age, Fazekas score, Time and baseline score. Age significantly but weakly  
39  
40 negatively affected FAC score change. Baseline score was a strong predictor of  
41  
42 response of FAC and MRMI scores, but not for Walk Speed. The negative  
43  
44 correlations indicated that the worse the initial score, the larger the absolute  
45  
46 behavioural gain from therapy. Finally, Time significantly predicted score change for  
47  
48 all three variables, again in the expected negative direction, but the correlations were  
49  
50 weak.  
51  
52

### 53 54 55 56 **wCST lesion load analysis** 57 58 59 60

1  
2  
3 One of the lesions was in the medulla and outside the standardised control CST, so  
4 this analysis was run on 49 subjects. **Tables 4a, b, c** show the results of the multiple  
5 regressions testing the correlation between the three response-to-therapy variables and  
6 wCST-LL adjusting for age, Fazekas score, Time and baseline score. Results from the  
7 multiple regression analysis revealed that CST damage did not significantly predict  
8 Walk Speed change ( $p=0.60$ ), but **significantly impacted changes in both FAC and**  
9 **MRMI ( $p= 0.030$  and  $0.024$ , respectively), albeit not strongly so, in the negative,**  
10 **i.e., biologically expected direction. Baseline score had a strong influence on FAC**  
11 **and MRMI, but only a weak - albeit significant - influence on Walk speed. Time**  
12 **modestly but significantly influenced FAC and MRMI.** Age significantly  
13 influenced FAC response only. Interestingly, Walk Speed was the least well predicted  
14 variable by the five covariates considered together.

### 31 VLSM

32 **Figure 1** shows the lesion overlap map overlaid on a standard MNI space brain,  
33 documenting that the most common lesion site involved the striato-capsular area. Out  
34 of the 50 subjects, four lesions had no overlap with any of the other lesions and the  
35 maximum number of overlapping lesions was 24. **Supplemental Figure 2** shows the  
36 overlap for voxels lesioned in at least 6 subjects, i.e., the ‘search volume’ for the  
37 VLSM analysis. This illustrates that the striato-capsular area, the frontal white matter  
38 up to the centrum semi-ovale, the external capsule, the insular cortex and extensive  
39 cortical areas including the precentral gyrus and the frontal opercula were all  
40 encompassed in the search volume. A power map from the lesion overlaps with the  
41 zero-thresholded left corticospinal tract (CST) overlaid from the John Hopkins  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 University (JHU) white-matter tracts atlas is shown in **Supplemental Figure 3**,  
4  
5 illustrating that the CST intersects close to the peak power area.  
6  
7

8  
9  
10 According to a design that included age, Fazekas scores, Time and baseline scores as  
11 nuisance covariates, the VLSM analysis revealed a single significant cluster for Walk  
12 Speed response to therapy, with a p value <0.02. Lesion in this area was significantly  
13 correlated with poorer recovery. **Table 5** labels the cluster's centre of mass in MNI  
14 space, together with the percentage of the cluster labelled according to the Hammers  
15 and JHU white-matter tracts atlases. The overlaps with the Anatomy are not shown  
16 because the cluster did not overlap with any Brodmann area identified in this atlas.  
17  
18 **Figure 2** depicts this cluster overlaid on a standard MNI template. The areas  
19 encompassed included the insula, lateral and anterior putamen and external capsule,  
20 and the superior longitudinal, inferior fronto-occipital and uncinate fasciculi. Of note,  
21 the cluster did not overlap with the CST. There were no significant findings with FAC  
22 or MRMI.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

To our knowledge this is the first study to combine CST damage measurement and VLSM to comprehensively assess the relationship between lesion topography and clinical measures of motricity post-stroke. **To this end, we used the wCST-LL method (Feng, et al., 2015; Zhu, et al., 2010) and VLSM (Bates, et al., 2003) to assess the role of CST and non-CST damage, respectively. Because the former assesses the CST in its entire intracranial length rather than locally as the latter does, it is expected to have much greater sensitivity and accuracy to assess the**

1  
2  
3 **role of CST lesion in behavioral outcome.** Our specific goal using this  
4  
5 complementary approach was to investigate whether lesion anatomy predicts the  
6  
7 response of stroke-induced impaired walking and mobility to rehabilitation. **One**  
8  
9 **strength of our study is the use of three different outcome measures, namely**  
10  
11 **walk speed as primary outcome, and FAC and MRMI, two functional scales**  
12  
13 **assessing distinct daily functions - namely getting out of bed and ambulating, and**  
14  
15 **walking under various environments, respectively - as secondary measures.** A  
16  
17 final strength is the substantial sample size available, affording adequate statistical  
18  
19 power.  
20  
21  
22  
23  
24

### 25 **General points**

26  
27 Before discussing the results, it is worth clarifying from the outset that our aim was  
28  
29 not to decipher the mechanisms underlying recovery of walking after stroke, but to  
30  
31 determine if stroke lesion topography predicts response to gait rehabilitation. We  
32  
33 addressed the following pragmatic clinical question: Can response to gait therapy be  
34  
35 predicted based on stroke lesion topography as determined on standard clinical MRI?  
36  
37 Accordingly, we did not assess variables such as functional activation patterns,  
38  
39 functional and structural connectivity changes, white matter tract degeneration or  
40  
41 structural changes remote from the lesion such as enlarged cortical thickness or white  
42  
43 matter bundles, that all can underlie plastic processes and hence contribute, or  
44  
45 impede, functional recovery (Calautti and Baron, 2003; Cramer, 2008; Johansen-  
46  
47 Berg, et al., 2002; Sharma, et al., 2009). Although these MR-based investigations  
48  
49 would be of interest to decipher the mechanisms underlying recovery of walking post-  
50  
51 stroke, they would not contribute to our pragmatic and directly clinical aim.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Three main results emerged from our study. First, baseline scores and time to baseline  
4 assessment, and less consistently age, predicted response to therapy for some or all  
5 clinical variables, confirming these are important covariates to consider when  
6 assessing the independent predictive value of lesion topography for behavioral gains.  
7  
8 Second, using a multiple regression model accounting for the above covariates plus  
9 white matter lesion score, **CST damage independently influenced FAC and MRMI**  
10 **response, but not Walk speed.** Importantly, of the three clinical measures, Walk  
11 Speed response was the least well predicted by the five-variable model, suggesting  
12 other variables are operative. Accordingly, assessing non-CST lesion involvement  
13 using VLSM revealed significant findings only for Walk Speed, namely a cluster  
14 involving the insula, putamen, external capsule and surrounding white matter tracts.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 The findings regarding the covariates deserve a brief comment. Baseline score had the  
31 strongest influence, consistent with previous studies on post-stroke walking and  
32 ambulation (Burke, et al., 2014; Dawes, et al., 2008; Jorgensen, et al., 1995; Kollen, et  
33 al., 2005). That time elapsed since stroke onset also influenced response to therapy  
34 was expected given that this study enrolled patients relatively early after stroke, and  
35 that recovery is steeper at the early post-stroke stage (Duncan, et al., 1992). Previous  
36 studies carried out in the chronic stage also reported an effect of time on recovery  
37 (Kollen, et al., 2005; O'Shea, et al., 2014; Stinear, et al., 2007). Again consistent with  
38 previous work (Dobkin, et al., 2014; Held, et al., 2012; Jorgensen, et al., 1995; Lam,  
39 et al., 2010; Stinear, et al., 2007), age impacted – albeit weakly so – recovery of  
40 ambulation. Finally, white matter FLAIR hyperintense lesion load did not  
41 significantly influence recovery, but was included *a priori* in the model given its  
42 previously reported impact (Held, et al., 2012).  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Involvement of the CST

**CST damage independently, albeit weakly, predicted FAC and MRMI response to therapy, but not Walk Speed.** This limited impact of CST damage on gait and ambulation recovery may seem unexpected given the reports regarding the upper limb consistently showing a strong effect (Lindenberg, et al., 2012; Nouri and Cramer, 2011; Riley, et al., 2011; Stinear, et al., 2007). It is unlikely that our findings are due to inadequate power, since the sample size was similar to that analyzed in a previous upper limb impairment study also using wCST-LL (Zhu, et al., 2010), and several-fold larger than three positive studies of upper limb response to therapy (Lindenberg, et al., 2012; Riley, et al., 2011; Stinear, et al., 2007) that all showed a significant role of the CST. **Our findings are in fact entirely consistent with a previous study that reported that CST damage predicted ambulation outcome assessed with FAC (Kim, et al., 2013), as well as with all previous reports that assessed the role of CST damage in walk speed outcome (Jayaram, et al., 2012) or response to therapy (Burke, et al., 2014; Dawes, et al., 2008), which were all negative.**

Previous work, also using the wCST-LL method, found that within the same population of stroke survivors, CST damage was more strongly related to upper limb than lower limb sensorimotor function (assessed with the Fugl-Meyer scale) (G. Schlaug et al, unpublished data). The weaker predictive value of CST damage for lower compared to upper extremity outcome might in part reflect the fact that canonical CST templates do not include other descending corticospinal tracts such as the corticorubral and the corticotegmental spinal tracts, which have slight differences in their cortical origins compared to the pyramidal tract (Ruber, et al., 2013; Ruber, et

1  
2  
3 al., 2012) and might innervate alpha motoneurons on both sides of the spinal cord,  
4  
5 either directly or indirectly, as well as proximal muscles more than distal muscles. As  
6  
7 compared to upper extremity sensorimotor function, walking involves quite different  
8  
9 motor control processes, including adapted body orientation relative to space and  
10  
11 environment, trunk stabilization around the body's centre of mass, generation of  
12  
13 alternate leg force to produce a cycling movement, and secure navigation in the  
14  
15 surroundings (Perennou and Hillier, 2014), which might account for a limited role of  
16  
17 the CST, and an important role for other structures, in this largely automatic function.  
18  
19 **Conversely, that CST damage influenced FAC and MRMI may reflect the more**  
20  
21 **composite nature of these scales that involve 'cortical effort', as they for instance**  
22  
23 **include on top of walking help with the upper limbs and trunk mobility, and are**  
24  
25 **assessed in real, complex environment such as bed surroundings or stairs.**  
26  
27  
28  
29  
30  
31

### 32 **Involvement of other structures**

33  
34 **Given the lack of impact of CST damage on Walk Speed response, and the**  
35  
36 **limited impact of the clinical variables tested, the finding that a non-CST located**  
37  
38 **cluster emerged from VLSM is not unexpected.** Based on VLSM, involvement of  
39  
40 the insula, lateral and anterior putamen and external capsule hindered Walk Speed  
41  
42 response, independently of the other covariates. **Note that the percentages for lesion**  
43  
44 **overlap shown in Table 5 are only approximate because the Hammer's Atlas**  
45  
46 **focuses on gray matter structures and does not consider fine anatomical details.**  
47  
48 **This is particularly true for the "insula" label, which encompasses also the**  
49  
50 **external capsule, claustrum and extreme capsule, leading to gross overestimation**  
51  
52 **of the overlap with the insula proper. Note also that the VLSM cluster did not**  
53  
54 **overlap with the areas of highest statistical power (Supplemental Figure 3),**  
55  
56  
57  
58  
59  
60

1  
2  
3 which involve the deep white matter and CST regions, and hence is not the result  
4  
5 of intrinsic bias. In addition, the permutation analysis was carried out on the  
6  
7 whole search area, not just on the voxels selected by the initial first-level  
8  
9 thresholding, i.e., there was no circularity or ‘double-dipping’ involved  
10  
11 (Kriegeskorte, et al., 2009). It is standard in VLSM studies to consider  
12  
13 correlations that survive this extremely stringent process as very robust.  
14  
15  
16  
17  
18  
19

20  
21 The putamen, as a node in the subcortico-cortical motor loop, is involved in  
22  
23 movement initiation, which is impaired in Parkinson’s disease (Alexander, et al.,  
24  
25 1990; DeLong and Wichmann, 2007), and involved in the implicit learning and  
26  
27 execution of well-learned sequences (i.e. procedural memory) including walking and  
28  
29 balance, accounting for its apparent role in re-learning to walk after stroke (Scherder,  
30  
31 et al., 2011). It is therefore not surprising that damage to the putamen impairs the  
32  
33 automatic act of walking. Previously, Alexander and colleagues reported an  
34  
35 association of gait asymmetry and leg weakness to lesions of the lateral putamen,  
36  
37 external capsule and insula in partly recovered stroke patients (Figure 2A in  
38  
39 (Alexander, et al., 2009)). Also, changes in putaminal fMRI activations during foot  
40  
41 movement were found to correlate well with improvements in walking speed  
42  
43 following treadmill-based rehabilitation after stroke (Enzinger, et al., 2009). **Using**  
44  
45 **VLSM, Wu et al recently reported that the putamen, insula and external capsule,**  
46  
47 **among other structures, contribute to poor functional outcome post-stroke (Wu,**  
48  
49 **et al., 2015), and Cheng et al found that lesions to the insula affected global**  
50  
51 **outcome (Cheng, et al., 2014).** Overall, therefore, our finding that damage to the  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 putamen, **insula** and external capsule affects recovery of walking is consistent with  
4  
5 previous work.  
6  
7

8  
9  
10 The VLSM analysis also suggested that damage to the superior longitudinal, inferior  
11  
12 fronto-occipital and uncinate fasciculi affected Walk Speed response. The functions  
13  
14 sustained by the two former tracts are not well understood, but they connect the  
15  
16 prefrontal and premotor regions to the occipital cortex, and as such could be involved  
17  
18 in balance and walking. Accordingly, white matter ischemic lesions particularly  
19  
20 involving the frontal lobe are associated with gait impairment (de Laat, et al., 2011).  
21  
22 More specifically, damage to the superior longitudinal fasciculus has been linked to  
23  
24 decreased postural stability and wide-based gait in elderly subjects (Scherder, et al.,  
25  
26 2011). Regarding the uncinate fasciculus, which connects the anterior part of the  
27  
28 frontal lobe to the medial and lateral temporal cortex, its damage in aged people has  
29  
30 been linked to decreased step length and walking velocity as well as more generally  
31  
32 with apractic gait (Scherder, et al., 2011). **Following a stroke, damage to the**  
33  
34 **superior longitudinal and uncinate fasciculi were recently reported to contribute**  
35  
36 **to worse global functional outcome (Wu, et al., 2015).**  
37  
38  
39  
40  
41  
42

43 **On a physiological standpoint, although the hard-wired basis for synergistic**  
44  
45 **stepping is engendered in the spinal cord by so-called ‘central pattern**  
46  
47 **generators’ (CPGs), walking involves a variety of supraspinal areas. Current**  
48  
49 **understanding proposes that supraspinal control may in fact be more important**  
50  
51 **than CPGs for human walking (reviewed by (Verma, et al., 2012). Evidence for**  
52  
53 **this interpretation includes the association of gait temporal asymmetry after**  
54  
55 **stroke with posterolateral putamen lesion (Alexander, et al., 2009). More**  
56  
57  
58  
59  
60

1  
2  
3 recently, it has also been shown that, together with the pedunclopontine nucleus  
4  
5 located in the brainstem, the sub-thalamic nucleus, which is part of Alexander's  
6  
7 motor loop referred to above and as such strongly connected to the putamen and  
8  
9 motor cortical areas, plays a significant role in imagined gait in humans (Lau, et  
10  
11 al., 2015).  
12  
13

### 14 15 16 **Stroke side**

17  
18 In order to ensure optimal statistical power, lesions were flipped so that they all  
19  
20 mapped onto the same hemisphere, as is widely done (Cheng, et al., 2014; Lo, et al.,  
21  
22 2010; Zhu, et al., 2010). However, half of the patients had their stroke on either side.  
23  
24 Although there is only scant evidence that ambulatory functions are hemisphere-  
25  
26 dependent, this hypothesis cannot be excluded. To address this we repeated post-hoc  
27  
28 the VLSM analysis separately for the left and right-sided strokes (n=26 in each),  
29  
30 which revealed no significant cluster for either (data not shown), likely from the loss  
31  
32 of statistical power.  
33  
34  
35  
36  
37  
38

### 39 **Mobility, ambulation and walk speed**

40  
41 In the present study we used three different measures of recovery, namely Walk  
42  
43 Speed as primary outcome, and FAC and MRMI as secondary measures.  
44  
45 Although response to therapy for these three scales was significantly inter-  
46  
47 correlated, the correlations between Walk Speed and the other two scales were  
48  
49 weak, while that between FAC and MRMI was strong but accounted for only  
50  
51 ~50% of the variance, in part reflecting the fact that these two scales share some  
52  
53 items (eg, walking independently). However they are constructed to assess  
54  
55 different everyday functions, i.e., MRMI assesses the ability to move in and get  
56  
57  
58  
59  
60

1  
2  
3 out of bed and walk, and includes items such as turning over in bed, lying to  
4  
5 sitting, sitting balance, sitting to standing, standing balance, walking indoors and  
6  
7 walking up the stairs, while FAC assesses ambulation in various surroundings  
8  
9 including in parallel bars, evaluating the degree of dependency on physical  
10  
11 assistance right through to independence. Accordingly, although their  
12  
13 relationships with wCST-LL and several co-variates are similar (Tables 4b and  
14  
15 c), their relationship with age is different, and differences between MRMI and  
16  
17 FAC vs Walk Speed (Table 4a) are even more striking. On a clinical point of  
18  
19 view it would have no relevance to merge MRMI and FAC into a single  
20  
21 compound variable because they are validated and used in whole in daily  
22  
23 rehabilitation practice, while Walk Speed represents speed of walking in a  
24  
25 laboratory setting (ie, walking forwards on a flat, even floor, in a protected  
26  
27 environment). These three scales were prospectively chosen for this study for  
28  
29 these specific reasons. Likewise, it would not be clinically acceptable to split  
30  
31 these scales into their component items with a view to derive independent  
32  
33 dimensions, because they have been prospectively constructed to represent a  
34  
35 single overall everyday function (e.g., getting out of bed and ambulate, as at  
36  
37 home) and then validated as a single value in extensive investigations.  
38  
39  
40  
41  
42  
43  
44

### 45 **Limitations**

46  
47 Stroke topography varied widely across patients in our sample (Supplemental Fig 2),  
48  
49 which could have increased the variance and reduced the statistical strength of this  
50  
51 study despite the sizeable sample. However, our sample was gathered prospectively  
52  
53 among consecutive referrals to rehabilitation centers, as part of a randomized clinical  
54  
55 trial. Accordingly, our sample is representative of routine referrals for post-stroke gait  
56  
57  
58  
59  
60

1  
2  
3 rehabilitation, making our results clinically relevant. Selecting *post hoc* a  
4 homogeneous sub-sample based on e.g., stroke topography or etiology would have  
5 hindered this clinical relevance and generalizability. On the other hand, this  
6 variability caused the VLSM search volume to be restricted to a circumscribed zone  
7 (Figure 2). Of note, the M1 leg area, which is located on the medial surface of the  
8 posterior frontal lobe and belongs to the ACA territory, was not part of the search  
9 volume, so the influence of its lesion on treatment response could not be assessed.  
10 However, consistent with the notion that ACA infarctions are relatively rare,  
11 individual analysis of native space MRI showed only 2 patients with leg area  
12 involvement, and this was in fact associated in both cases with extensive subcortical  
13 damage (Supplemental Figure 2).  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Applying VLSM requires that a minimum number of subjects with a lesion in any  
31 particular voxel be set *a priori*, simply because the statistical analysis is based on two-  
32 sample comparisons and the ‘lesioned’ sample has to be reasonably large to make  
33 robust inferences. Although there is no strict recommendation on how to determine  
34 this threshold in each particular study, we used six subjects in the present study  
35 because this is a statistically reasonable sample. In order to further explore this issue,  
36 we carried out a *post-hoc* sensitivity analysis using 10 subjects as threshold. The same  
37 cluster as with six subjects emerged, although as expected smaller. We also carried  
38 out additional *post-hoc* sensitivity analyses using  $<0.001$  as initial default p threshold.  
39 Again the same cluster emerged, of smaller extent but including the same anatomical  
40 structures. The same was true using a threshold of 10 subjects and  $p<0.001$  as initial  
41 default. These sensitivity analyses therefore strongly support the robustness of our  
42 VLSM findings. Regarding the topographical accuracy of VLSM, it has been argued  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 that studying patients with large-artery ischemic strokes might cause several-mm  
4 displacement of the significant clusters because of the intrinsic vascular architecture  
5 affecting the shape of resulting infarcts (Mah, et al., 2014). In this situation, distinct  
6 approaches to image processing requiring very large datasets and simple,  
7 dichotomized outcomes have been proposed (Mah, et al., 2014). However, the present  
8 study enrolled patients with highly variable stroke mechanisms (including 9 with  
9 haemorrhage) and infarct locations and etiologies (including 17 with lacunar infarcts),  
10 which would have mitigated any such effect. Minor errors in the precise anatomical  
11 localisation of the VLSM cluster cannot however be excluded.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24  
25 **We do not provide formal validation of our findings in two independent samples.**  
26  
27 **Given that the maximum number of patients with a lesion in any given voxel was**  
28 **24 (Figure 1), it was not feasible to split the sample in two to assess**  
29 **reproducibility with adequate power. We have however carried out an internal**  
30 **validation of the VLSM cluster using the ‘leave-one-out’ approach, which**  
31 **showed a stable peak location (center of mass within 1.4mm of whole group**  
32 **cluster for 48/50 analyses). Nevertheless, replicability of our findings is an**  
33 **important goal for future studies. Finally, although we identify regions that may**  
34 **help predict treatment response, we do not claim that we can individually**  
35 **classify responders according to lesion location. To be able to do this and for**  
36 **instance report sensitivity and specificity, dichotomized classification of response**  
37 **to therapy as responders and non-responders would be required. However,**  
38 **there is no universally accepted, validated dichotomized Walk Speed, FAC or**  
39 **MRMI response available at this time.**  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This study was carried out as part of a pragmatic randomised trial assessing whether  
4 the benefits of routine physical therapy could be augmented by an ankle-foot orthosis  
5 (AFO), custom-made and fitted by a therapist within a 24-hour period, to provide  
6 optimal alignment of the lower limb to the ground during walking (Pomeroy, et al.,  
7 2012). Thus both groups received *routine physical therapy* ('treatment-as-usual')  
8 provided by the clinical physiotherapists. **As presented in detail elsewhere**  
9 **(Pomeroy, et al., 2015)**, there were no statistically significant differences between the  
10 two groups in the content of physical therapy they received, except that the control  
11 group had higher use of off-the-shelf AFOs and the experimental group had as  
12 expected a higher use of a SWIFT Cast, and there were no statistically significant  
13 differences between the groups for any outcome measure, not even evidence of trends  
14 (Pomeroy et al submitted). The experimental device therefore did not influence  
15 response to therapy, and our findings are therefore applicable to standard physical  
16 therapy in routine clinical practice.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **In our study there was a wide variance in the nominal number of sessions given**  
38 **to and treatment duration among patients (Pomeroy, et al., 2015), which could**  
39 **have influenced response to therapy. However this was a pragmatic trial**  
40 **conducted in the routine rehabilitation environment where participants were**  
41 **resident either a hospital stroke rehabilitation ward or their own homes. As is**  
42 **commonplace in similar trials, the study could not make it compulsory for**  
43 **therapists to record in a systematic and standardized way each and every minute**  
44 **of routine therapy directed at enhancement of lower limb function they gave to**  
45 **the participants of the trial. Thus the data collected is for therapy provided when**  
46 **a therapist was present and does not include any additional, self-administered**  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 therapy. Consequently, the data was judged insufficiently accurate to be used as  
4  
5 a covariate. Nevertheless, applying standard methods for missing data in the  
6  
7 present MRI subset, we found no significant relationship between treatment  
8  
9 duration and response to therapy for any of the three clinical measures (data not  
10  
11 shown). This is in fact not surprising as there is no clear relationship between the  
12  
13 amount of standard post-stroke physiotherapy and clinical response (English  
14  
15 and Veerbeek, 2015), partly because more disabled subjects tend to get more  
16  
17 intensive therapy, whilst less affected subjects are trained and instructed to  
18  
19 recourse to self-administered walking and balance exercises. Despite the above  
20  
21 caveats, we tested the effects of adding treatment duration as a further covariate  
22  
23 in the multivariate analyses, which did not substantially change the results of the  
24  
25 wCST-LL analyses and VLSM.  
26  
27  
28  
29  
30  
31

32 In our study the MRI was carried out only after recruitment and start of  
33  
34 therapy. This was considered unimportant for the assessment of the predictive  
35  
36 value of stroke lesion location for response to therapy because stroke lesions are  
37  
38 stable from about two weeks after onset (after vasogenic edema has vanished) up  
39  
40 to around 12 weeks (before significant shrinkage occurs) (Gaudinski, et al.,  
41  
42 2008). Because of difficulties in obtaining scanning slots for this research study,  
43  
44 some scans were carried out slightly later than planned, which could have  
45  
46 affected the accuracy of lesion masks in some cases. In the event of real-life  
47  
48 application of our paradigm, however, MR scanning would need to be carried  
49  
50 out before the rehabilitation regimen is decided, in order to guide it. In the  
51  
52 clinical setting, if MRI is not available other approaches to predict response of  
53  
54 walking speed to gait therapy could be considered such as TMS (Hendricks, et  
55  
56  
57  
58  
59  
60

1  
2  
3 al., 2003a; Hendricks, et al., 2003b; Piron, et al., 2005), which however does not  
4  
5 provide information regarding non-CST located damage.  
6  
7

## 8 9 10 **Conclusion**

11 The findings from the present study suggest that strokes affecting the lateral putamen  
12 and neighbouring structures reduce response of walking speed to standard  
13 rehabilitation, **while cortico-spinal tract damage has statistically significant,**  
14 **though somewhat limited, impact on two functional scales assessing general**  
15 **mobility and gait.**  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 **Acknowledgements:** The staff and patients involved in the SWIFT-Cast trial are  
26 gratefully acknowledged.  
27  
28  
29  
30  
31

32 **Funding:** This study was supported by the Efficacy and Mechanism Evaluation  
33 (EME) Programme, an MRC-UK and NIHR partnership. The EME Programme is  
34 funded by the MRC and NIHR, with contributions from the CSO in Scotland and  
35 NISCHR in Wales and the HSC R&D Division, Public Health Agency in Northern  
36 Ireland. The views expressed in this publication are those of the authors and not  
37 necessarily those of the MRC, NHS, NIHR or the Department of Health. PS Jones  
38 was supported by the Cambridge Biomedical Research Centre.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 **Conflicts of Interest:** None.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Literature cited

- Alexander, G.E., Crutcher, M.D., DeLong, M.R. (1990) Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. *Progress in brain research*, 85:119-46.
- Alexander, L.D., Black, S.E., Patterson, K.K., Gao, F., Danells, C.J., McIlroy, W.E. (2009) Association between gait asymmetry and brain lesion location in stroke patients. *Stroke*, 40:537-44.
- Andersen, S.M., Rapcsak, S.Z., Beeson, P.M. (2010) Cost function masking during normalization of brains with focal lesions: still a necessity? *Neuroimage*, 53:78-84.
- Bates, E., Wilson, S.M., Saygin, A.P., Dick, F., Sereno, M.I., Knight, R.T., Dronkers, N.F. (2003) Voxel-based lesion-symptom mapping. *Nature neuroscience*, 6:448-50.
- Brett, M., Leff, A.P., Rorden, C., Ashburner, J. (2001) Spatial normalization of brain images with focal lesions using cost function masking. *Neuroimage*, 14:486-500.
- Burke, E., Dobkin, B.H., Noser, E.A., Enney, L.A., Cramer, S.C. (2014) Predictors and biomarkers of treatment gains in a clinical stroke trial targeting the lower extremity. *Stroke*, 45:2379-84.
- Calautti, C., Baron, J.C. (2003) Functional neuroimaging studies of motor recovery after stroke in adults: a review. *Stroke*, 34:1553-66.
- Cheng, B., Forkert, N.D., Zavaglia, M., Hilgetag, C.C., Golsari, A., Siemonsen, S., Fiehler, J., Pedraza, S., Puig, J., Cho, T.H., Alawneh, J., Baron, J.C.,

- 1  
2  
3 Ostergaard, L., Gerloff, C., Thomalla, G. (2014) Influence of stroke infarct  
4 location on functional outcome measured by the modified rankin scale. *Stroke*,  
5 45:1695-702.  
6  
7  
8  
9  
10 Cramer, S.C. (2008) Repairing the human brain after stroke: I. Mechanisms of  
11 spontaneous recovery. *Ann Neurol*, 63:272-87.  
12  
13  
14 Cramer, S.C., Parrish, T.B., Levy, R.M., Stebbins, G.T., Ruland, S.D., Lowry, D.W.,  
15 Trouard, T.P., Squire, S.W., Weinand, M.E., Savage, C.R., Wilkinson, S.B.,  
16 Juranek, J., Leu, S.Y., Himes, D.M. (2007) Predicting functional gains in a  
17 stroke trial. *Stroke*, 38:2108-14.  
18  
19  
20  
21  
22  
23 Dawes, H., Enzinger, C., Johansen-Berg, H., Bogdanovic, M., Guy, C., Collett, J.,  
24 Izadi, H., Stagg, C., Wade, D., Matthews, P.M. (2008) Walking performance  
25 and its recovery in chronic stroke in relation to extent of lesion overlap with  
26 the descending motor tract. *Exp Brain Res*, 186:325-33.  
27  
28  
29  
30  
31  
32 de Laat, K.F., Tuladhar, A.M., van Norden, A.G., Norris, D.G., Zwiers, M.P., de  
33 Leeuw, F.E. (2011) Loss of white matter integrity is associated with gait  
34 disorders in cerebral small vessel disease. *Brain*, 134:73-83.  
35  
36  
37  
38  
39 DeLong, M.R., Wichmann, T. (2007) Circuits and circuit disorders of the basal  
40 ganglia. *Archives of neurology*, 64:20-4.  
41  
42  
43 Deoni, S.C., Williams, S.C., Jezzard, P., Suckling, J., Murphy, D.G., Jones, D.K.  
44 (2008) Standardized structural magnetic resonance imaging in multicentre  
45 studies using quantitative T1 and T2 imaging at 1.5 T. *Neuroimage*, 40:662-  
46 71.  
47  
48  
49  
50  
51  
52 Dobkin, B.H., Firestine, A., West, M., Saremi, K., Woods, R. (2004) Ankle  
53 dorsiflexion as an fMRI paradigm to assay motor control for walking during  
54 rehabilitation. *Neuroimage*, 23:370-81.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Dobkin, B.H., Nadeau, S.E., Behrman, A.L., Wu, S.S., Rose, D.K., Bowden, M.,  
4  
5 Studenski, S., Lu, X., Duncan, P.W. (2014) Prediction of responders for  
6  
7 outcome measures of locomotor Experience Applied Post Stroke trial. Journal  
8  
9 of rehabilitation research and development, 51:39-50.  
10  
11  
12 Duncan, P.W., Goldstein, L.B., Matchar, D., Divine, G.W., Feussner, J. (1992)  
13  
14 Measurement of motor recovery after stroke. Outcome assessment and sample  
15  
16 size requirements. Stroke, 23:1084-9.  
17  
18  
19 Eickhoff, S.B., Stephan, K.E., Mohlberg, H., Grefkes, C., Fink, G.R., Amunts, K.,  
20  
21 Zilles, K. (2005) A new SPM toolbox for combining probabilistic  
22  
23 cytoarchitectonic maps and functional imaging data. Neuroimage, 25:1325-35.  
24  
25  
26 English, C., Veerbeek, J. (2015) Is more physiotherapy better after stroke?  
27  
28 International journal of stroke : official journal of the International Stroke  
29  
30 Society, 10:465-6.  
31  
32  
33 Enzinger, C., Dawes, H., Johansen-Berg, H., Wade, D., Bogdanovic, M., Collett, J.,  
34  
35 Guy, C., Kischka, U., Ropele, S., Fazekas, F., Matthews, P.M. (2009) Brain  
36  
37 activity changes associated with treadmill training after stroke. Stroke,  
38  
39 40:2460-7.  
40  
41  
42 Fazekas, F. (1989) Magnetic resonance signal abnormalities in asymptomatic  
43  
44 individuals: their incidence and functional correlates. Eur Neurol, 29:164-8.  
45  
46  
47 Feng, W., Wang, J., Chhatbar, P.Y., Doughty, C., Landsittel, D., Lioutas, V.A.,  
48  
49 Kautz, S., Schlaug, G. (2015) Corticospinal tract lesion load - A potential  
50  
51 imaging biomarker for stroke motor outcomes. Ann Neurol.  
52  
53  
54 Fugl-Meyer, A.R., Jaasko, L., Leyman, I., Olsson, S., Steglind, S. (1975) The post-  
55  
56 stroke hemiplegic patient. 1. a method for evaluation of physical performance.  
57  
58  
59 Scand J Rehabil Med, 7:13-31.  
60

- 1  
2  
3 Gale, S.D., Pearson, C.M. (2012) Neuroimaging predictors of stroke outcome:  
4  
5 implications for neurorehabilitation. *NeuroRehabilitation*, 31:331-44.  
6  
7  
8 Gaudinski, M.R., Henning, E.C., Miracle, A., Luby, M., Warach, S., Latour, L.L.  
9  
10 (2008) Establishing final infarct volume: stroke lesion evolution past 30 days  
11  
12 is insignificant. *Stroke*, 39:2765-8.  
13  
14 Hammers, A., Allom, R., Koepp, M.J., Free, S.L., Myers, R., Lemieux, L., Mitchell,  
15  
16 T.N., Brooks, D.J., Duncan, J.S. (2003) Three-dimensional maximum  
17  
18 probability atlas of the human brain, with particular reference to the temporal  
19  
20 lobe. *Hum Brain Mapp*, 19:224-47.  
21  
22  
23 Heckemann, R.A., Hajnal, J.V., Aljabar, P., Rueckert, D., Hammers, A. (2006)  
24  
25 Automatic anatomical brain MRI segmentation combining label propagation  
26  
27 and decision fusion. *Neuroimage*, 33:115-26.  
28  
29  
30 Held, V., Szabo, K., Bazner, H., Hennerici, M.G. (2012) Chronic small vessel disease  
31  
32 affects clinical outcome in patients with acute striatocapsular stroke.  
33  
34 *Cerebrovasc Dis*, 33:86-91.  
35  
36  
37 Hendricks, H.T., Pasman, J.W., Merx, J.L., van Limbeek, J., Zwarts, M.J. (2003a)  
38  
39 Analysis of recovery processes after stroke by means of transcranial magnetic  
40  
41 stimulation. *Journal of clinical neurophysiology : official publication of the*  
42  
43 *American Electroencephalographic Society*, 20:188-95.  
44  
45  
46 Hendricks, H.T., Pasman, J.W., van Limbeek, J., Zwarts, M.J. (2003b) Motor evoked  
47  
48 potentials of the lower extremity in predicting motor recovery and ambulation  
49  
50 after stroke: a cohort study. *Archives of physical medicine and rehabilitation*,  
51  
52 84:1373-9.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Holden, M.K., Gill, K.M., Magliozzi, M.R., Nathan, J., Piehl-Baker, L. (1984)  
4  
5 Clinical gait assessment in the neurologically impaired. Reliability and  
6  
7 meaningfulness. *Physical therapy*, 64:35-40.  
8  
9  
10 Hua, K., Zhang, J., Wakana, S., Jiang, H., Li, X., Reich, D.S., Calabresi, P.A., Pekar,  
11  
12 J.J., van Zijl, P.C., Mori, S. (2008) Tract probability maps in stereotaxic  
13  
14 spaces: analyses of white matter anatomy and tract-specific quantification.  
15  
16 *Neuroimage*, 39:336-47.  
17  
18  
19 Jayaram, G., Stagg, C.J., Esser, P., Kischka, U., Stinear, J., Johansen-Berg, H. (2012)  
20  
21 Relationships between functional and structural corticospinal tract integrity  
22  
23 and walking post stroke. *Clin Neurophysiol*, 123:2422-8.  
24  
25  
26 Johansen-Berg, H., Rushworth, M.F., Bogdanovic, M.D., Kischka, U., Wimalaratna,  
27  
28 S., Matthews, P.M. (2002) The role of ipsilateral premotor cortex in hand  
29  
30 movement after stroke. *Proc Natl Acad Sci U S A*, 99:14518-23.  
31  
32  
33 Jorgensen, H.S., Nakayama, H., Raaschou, H.O., Olsen, T.S. (1995) Recovery of  
34  
35 walking function in stroke patients: the Copenhagen Stroke Study. *Archives of*  
36  
37 *physical medicine and rehabilitation*, 76:27-32.  
38  
39  
40 Kim, E.H., Lee, J., Jang, S.H. (2013) Motor outcome prediction using diffusion tensor  
41  
42 tractography of the corticospinal tract in large middle cerebral artery territory  
43  
44 infarct. *NeuroRehabilitation*, 32:583-90.  
45  
46  
47 Kollen, B., van de Port, I., Lindeman, E., Twisk, J., Kwakkel, G. (2005) Predicting  
48  
49 improvement in gait after stroke: a longitudinal prospective study. *Stroke*,  
50  
51 36:2676-80.  
52  
53  
54 Kriegeskorte, N., Simmons, W.K., Bellgowan, P.S., Baker, C.I. (2009) Circular  
55  
56 analysis in systems neuroscience: the dangers of double dipping. *Nature*  
57  
58 *neuroscience*, 12:535-40.  
59  
60

- 1  
2  
3 Lam, J.M., Globas, C., Cerny, J., Hertler, B., Uludag, K., Forrester, L.W., Macko,  
4  
5 R.F., Hanley, D.F., Becker, C., Luft, A.R. (2010) Predictors of response to  
6  
7 treadmill exercise in stroke survivors. *Neurorehabil Neural Repair*, 24:567-74.  
8  
9  
10 Lau, B., Welter, M.L., Belaid, H., Fernandez Vidal, S., Bardinet, E., Grabli, D.,  
11  
12 Karachi, C. (2015) The integrative role of the pedunclopontine nucleus in  
13  
14 human gait. *Brain*, 138:1284-96.  
15  
16 Lee, J.S., Han, M.K., Kim, S.H., Kwon, O.K., Kim, J.H. (2005) Fiber tracking by  
17  
18 diffusion tensor imaging in corticospinal tract stroke: Topographical  
19  
20 correlation with clinical symptoms. *Neuroimage*, 26:771-6.  
21  
22  
23 Lennon, S., Johnson, L. (2000) The modified rivermead mobility index: validity and  
24  
25 reliability. *Disability and rehabilitation*, 22:833-9.  
26  
27  
28 Lindenberg, R., Renga, V., Zhu, L.L., Betzler, F., Alsop, D., Schlaug, G. (2010)  
29  
30 Structural integrity of corticospinal motor fibers predicts motor impairment in  
31  
32 chronic stroke. *Neurology*, 74:280-7.  
33  
34  
35 Lindenberg, R., Zhu, L.L., Ruber, T., Schlaug, G. (2012) Predicting functional motor  
36  
37 potential in chronic stroke patients using diffusion tensor imaging. *Hum Brain*  
38  
39 *Mapp*, 33:1040-51.  
40  
41  
42 Lo, R., Gitelman, D., Levy, R., Hulvershorn, J., Parrish, T. (2010) Identification of  
43  
44 critical areas for motor function recovery in chronic stroke subjects using  
45  
46 voxel-based lesion symptom mapping. *Neuroimage*, 49:9-18.  
47  
48  
49 Mah, Y.H., Husain, M., Rees, G., Nachev, P. (2014) Human brain lesion-deficit  
50  
51 inference remapped. *Brain*, 137:2522-31.  
52  
53  
54 Maraka, S., Jiang, Q., Jafari-Khouzani, K., Li, L., Malik, S., Hamidian, H., Zhang, T.,  
55  
56 Lu, M., Soltanian-Zadeh, H., Chopp, M., Mitsias, P.D. (2014) Degree of  
57  
58  
59  
60

1  
2  
3 corticospinal tract damage correlates with motor function after stroke. *Annals*  
4  
5 of clinical and translational neurology, 1:891-9.  
6

7 Mehrholz, J., Wagner, K., Rutte, K., Meissner, D., Pohl, M. (2007) Predictive validity  
8  
9 and responsiveness of the functional ambulation category in hemiparetic  
10  
11 patients after stroke. *Archives of physical medicine and rehabilitation*,  
12  
13 88:1314-9.  
14  
15

16 Mihara, M., Miyai, I., Hattori, N., Hatakenaka, M., Yagura, H., Kawano, T., Kubota,  
17  
18 K. (2012) Cortical control of postural balance in patients with hemiplegic  
19  
20 stroke. *Neuroreport*, 23:314-9.  
21  
22

23 Miyai, I., Yagura, H., Hatakenaka, M., Oda, I., Konishi, I., Kubota, K. (2003)  
24  
25 Longitudinal optical imaging study for locomotor recovery after stroke.  
26  
27 *Stroke*, 34:2866-70.  
28  
29

30 Nachev, P. (2014) The first step in modern lesion-deficit analysis. *Brain*.

31  
32 Nouri, S., Cramer, S.C. (2011) Anatomy and physiology predict response to motor  
33  
34 cortex stimulation after stroke. *Neurology*, 77:1076-83.  
35  
36

37 O'Shea, J., Boudrias, M.H., Stagg, C.J., Bachtiar, V., Kischka, U., Blicher, J.U.,  
38  
39 Johansen-Berg, H. (2014) Predicting behavioural response to TDCS in chronic  
40  
41 motor stroke. *Neuroimage*, 85 Pt 3:924-33.  
42  
43

44 Perennou, D.A., Hillier, S.L. (2014) Volumes of intact gray matter outside the stroke  
45  
46 predict gait performance. *Neurology*, 82:822-3.  
47  
48

49 Pineiro, R., Pendlebury, S.T., Smith, S., Flitney, D., Blamire, A.M., Styles, P.,  
50  
51 Matthews, P.M. (2000) Relating MRI changes to motor deficit after ischemic  
52  
53 stroke by segmentation of functional motor pathways. *Stroke*, 31:672-9.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Piron, L., Piccione, F., Tonin, P., Dam, M. (2005) Clinical correlation between motor  
4  
5 evoked potentials and gait recovery in poststroke patients. Archives of  
6  
7 physical medicine and rehabilitation, 86:1874-8.  
8

9  
10 Pomeroy, V.M., Rowe, P., Baron, J.C., Clark, A., Sealy, R., Ugbolue, U.C., Kerr, A.,  
11  
12 Investigators, S.C. (2012) The SWIFT Cast trial protocol: a randomized  
13  
14 controlled evaluation of the efficacy of an ankle-foot cast on walking recovery  
15  
16 early after stroke and the neural-biomechanical correlates of response.  
17  
18 International journal of stroke : official journal of the International Stroke  
19  
20 Society, 7:86-93.  
21

22  
23 Pomeroy, V.M., Rowe, P., Clark, A., Walker, A., Kerr, A., Chandler, E., Barber, M.,  
24  
25 Baron, J.C., Investigators, S.C. (2015) A Randomized Controlled Evaluation  
26  
27 of the Efficacy of an Ankle-Foot Cast on Walking Recovery Early After  
28  
29 Stroke: SWIFT Cast Trial. Neurorehabil Neural Repair.  
30

31  
32 Puig, J., Blasco, G., Daunis, I.E.J., Thomalla, G., Castellanos, M., Figueras, J.,  
33  
34 Remollo, S., van Eendenburg, C., Sanchez-Gonzalez, J., Serena, J., Pedraza, S.  
35  
36 (2013) Decreased corticospinal tract fractional anisotropy predicts long-term  
37  
38 motor outcome after stroke. Stroke, 44:2016-8.  
39

40  
41 Puig, J., Pedraza, S., Blasco, G., Daunis, I.E.J., Prados, F., Remollo, S., Prats-Galino,  
42  
43 A., Soria, G., Boada, I., Castellanos, M., Serena, J. (2011) Acute damage to  
44  
45 the posterior limb of the internal capsule on diffusion tensor tractography as an  
46  
47 early imaging predictor of motor outcome after stroke. AJNR Am J  
48  
49 Neuroradiol, 32:857-63.  
50

51  
52 Puig, J., Pedraza, S., Blasco, G., Daunis, I.E.J., Prats, A., Prados, F., Boada, I.,  
53  
54 Castellanos, M., Sanchez-Gonzalez, J., Remollo, S., Laguillo, G., Quiles,  
55  
56 A.M., Gomez, E., Serena, J. (2010) Wallerian degeneration in the  
57  
58  
59  
60

1  
2  
3 corticospinal tract evaluated by diffusion tensor imaging correlates with motor  
4 deficit 30 days after middle cerebral artery ischemic stroke. *AJNR Am J*  
5  
6  
7 *Neuroradiol*, 31:1324-30.

8  
9  
10 Qiu, M., Darling, W.G., Morecraft, R.J., Ni, C.C., Rajendra, J., Butler, A.J. (2011)  
11  
12 White matter integrity is a stronger predictor of motor function than BOLD  
13  
14 response in patients with stroke. *Neurorehabil Neural Repair*, 25:275-84.

15  
16 Riley, J.D., Le, V., Der-Yeghiaian, L., See, J., Newton, J.M., Ward, N.S., Cramer,  
17  
18 S.C. (2011) Anatomy of stroke injury predicts gains from therapy. *Stroke*,  
19  
20  
21 42:421-6.

22  
23 Rorden, C., Karnath, H.O., Bonilha, L. (2007) Improving lesion-symptom mapping.  
24  
25 *Journal of cognitive neuroscience*, 19:1081-8.

26  
27 Rosso, C., Valabregue, R., Attal, Y., Vargas, P., Gaudron, M., Baronnet, F., Bertasi,  
28  
29 E., Humbert, F., Peskine, A., Perlberg, V., Benali, H., Lehericy, S., Samson,  
30  
31 Y. (2013) Contribution of corticospinal tract and functional connectivity in  
32  
33 hand motor impairment after stroke. *PLoS One*, 8:e73164.

34  
35  
36 Ruber, T., Lindenberg, R., Schlaug, G. (2013) Differential Adaptation of Descending  
37  
38 Motor Tracts in Musicians. *Cereb Cortex*.

39  
40 Ruber, T., Schlaug, G., Lindenberg, R. (2012) Compensatory role of the cortico-  
41  
42 rubro-spinal tract in motor recovery after stroke. *Neurology*, 79:515-22.

43  
44  
45 Schaechter, J.D., Fricker, Z.P., Perdue, K.L., Helmer, K.G., Vangel, M.G., Greve,  
46  
47 D.N., Makris, N. (2009) Microstructural status of ipsilesional and  
48  
49 contralesional corticospinal tract correlates with motor skill in chronic stroke  
50  
51 patients. *Hum Brain Mapp*, 30:3461-74.

52  
53  
54 Scherder, E., Eggermont, L., Visscher, C., Scheltens, P., Swaab, D. (2011)  
55  
56 Understanding higher level gait disturbances in mild dementia in order to  
57  
58  
59  
60

1  
2  
3 improve rehabilitation: 'last in-first out'. *Neuroscience and biobehavioral*  
4  
5 reviews, 35:699-714.  
6

7 Schulz, R., Park, C.H., Boudrias, M.H., Gerloff, C., Hummel, F.C., Ward, N.S. (2012)

8  
9 Assessing the integrity of corticospinal pathways from primary and secondary  
10  
11 cortical motor areas after stroke. *Stroke*, 43:2248-51.  
12

13  
14 Sharma, N., Baron, J.C., Rowe, J.B. (2009) Motor imagery after stroke: relating

15  
16 outcome to motor network connectivity. *Ann Neurol*, 66:604-16.  
17

18 Stinear, C.M., Barber, P.A., Smale, P.R., Coxon, J.P., Fleming, M.K., Byblow, W.D.

19  
20 (2007) Functional potential in chronic stroke patients depends on corticospinal  
21  
22 tract integrity. *Brain*, 130:170-80.  
23

24  
25 Ugbohue, U.C., Papi, E., Kaliarntas, K.T., Kerr, A., Earl, L., Pomeroy, V.M., Rowe,

26  
27 P.J. (2013) The evaluation of an inexpensive, 2D, video based gait assessment  
28  
29 system for clinical use. *Gait & posture*, 38:483-9.  
30

31  
32 Verma, R., Arya, K.N., Sharma, P., Garg, R.K. (2012) Understanding gait control in

33  
34 post-stroke: implications for management. *Journal of bodywork and*  
35  
36 movement therapies, 16:14-21.  
37

38 Walsh, J.M., Barrett, A., Murray, D., Ryan, J., Moroney, J., Shannon, M. (2010) The

39  
40 Modified Rivermead Mobility Index: reliability and convergent validity in a  
41  
42 mixed neurological population. *Disability and rehabilitation*, 32:1133-9.  
43

44  
45 Wu, O., Cloonan, L., Mocking, S.J., Bouts, M.J., Copen, W.A., Cougo-Pinto, P.T.,

46  
47 Fitzpatrick, K., Kanakis, A., Schaefer, P.W., Rosand, J., Furie, K.L., Rost,

48  
49 N.S. (2015) Role of Acute Lesion Topography in Initial Ischemic Stroke  
50  
51 Severity and Long-Term Functional Outcomes. *Stroke*, 46:2438-44.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Zhu, L.L., Lindenberg, R., Alexander, M.P., Schlaug, G. (2010) Lesion load of the corticospinal tract predicts motor impairment in chronic stroke. Stroke, 41:910-5.

For Peer Review

**Table 1.** Baseline characteristics of the subjects (N=50) showing showing median (interquartile range) and range unless otherwise stated

<b>Male/Female</b>	28/22
<b>Left/Right</b>	25/25
<b>Infarct/Haemorrhage</b>	41/9
<b>Age (years)</b>	64.6 (15.0) <sup>†</sup> , 27-100
<b>Time to Baseline assessment (days)</b>	16.0 (9-25), 3-42
<b>Fazekas score</b>	2 (1-2), 0-3
<b>Lesion Volume (cm<sup>3</sup>)</b>	4.4 (0.8-28.1), 0.05-188.18

<sup>†</sup> Mean (SD).

**Table 2.** Summary functional performance measure (median and interquartile range unless otherwise stated; N= 50)

	Baseline	Outcome	Change	Effect size	p-value&
<b>Walk Speed (m/s)</b>	0.00 (.00-.25)	0.49 (.18-.71)	0.24 (.00-.51)	0.69	<0.000
<b>MRMI</b>	24 (19-32)	37 (34-38)	10 (4-15)	0.73	<0.000
<b>FAC</b>	1 (0-2)	4 (4-4)	3 (1-4)	0.58	<0.000

FAC = Functional Ambulation Category; MRMI = Modified Rivermead Mobility Index. Change means the difference between Outcome and Baseline, i.e. response to therapy. Effect sizes are from Cohen's  $r^2 = \text{Wilcoxon } Z / \sqrt{N}$ . Cohen's d 0.2-0.5 = small effect size  $\sim r^2$  0.01-0.06; 0.5-0.8 = medium effect size  $\sim r^2$  0.06-0.17; >0.17 = large effect size. &: Wilcoxon signed rank test.

**Table 3.** Correlation of Response to Therapy for the three behavioural measures with four baseline variables (Kendall's Tau)

	Age (years)	Fazekas Score	Baseline Score	Time from Stroke to Baseline
<b>Walk Speed</b>	-0.19 (p=0.06)	-0.18 (p=0.10)	-0.21 (p=0.07)	-0.23 (p<0.03)
<b>FAC</b>	-0.25 (p<0.02)	-0.04 (p=0.76)	-0.60 (p<0.001)	-0.26 (p<0.02)
<b>MRMI</b>	-0.11 (p=0.29)	0.01 (p=0.91)	-0.65 (p<0.001)	-0.26 (p<0.01)

**Table 4a.** Multiple Regressions to predict Walk Speed response to therapy (N = 49 subjects)<sup>†</sup>

	$\beta$	Standard Error	Standardized $\beta$ coefficients	Partial $r$	$p$	Pearson $r$
wCST-LL	-0.007	0.014	-0.085	-0.079	0.606	-0.004
Age	-0.002	0.003	-0.108	-0.100	0.512	-0.247
Fazekas Score	-0.060	0.050	-0.193	-0.180	0.236	-0.262
Baseline score	-0.376	0.185	-0.274	-0.296*	0.049	-0.295
Time	-0.006	0.004	-0.249	-0.250	0.098	-0.327

<sup>†</sup>Response to therapy as dependent variable from a multiple regression with predictors wCST load, age, Fazekas score, baseline Walk Speed, and Time. For each variable, the Beta, standard error for Beta, and standardized Beta Coefficient is given together with the significance for this component, the raw Pearson correlation of the dependant variable with response to therapy, and the partial correlation independently of other variables. \*:  $p < 0.05$ .

**Table 4b.** Ordinal Regression to predict FAC response to therapy<sup>§</sup>

	OR	95% CI	Wald $\chi^2(1)$	$p$ -value	Pearson $r$
wCST-LL	0.80	0.66-0.98	4.71	0.030*	-0.155
Age	0.94	0.89-0.98	6.78	0.009*	-0.302*
Fazekas Score	1.29	0.64-2.60	0.50	0.478	-0.046
Baseline score	0.21	0.11-0.38	25.54	0.000**	-0.658**
Time	0.94	0.89-1.00	4.37	0.037*	-0.331*

<sup>§</sup>Response to therapy as dependent variable from an ordinal regression with predictors wCST load, age, Fazekas score, baseline Walk Speed, and Time. For each variable, the Odds Ratio (OR), 95% Confidence Interval for the OR, and the  $\chi^2$  is given together with its significance for this component, and the raw Pearson correlation of the dependant variable with response to therapy. \*significant  $p < 0.05$ , \*\*  $p < 0.001$ . The OR for Age implies the odds of recovery decrease by 0.94 for each increase in age of one year. Units for Time to Baseline are days, and wCST  $\text{cm}^3$ .

**Table 4c.** Multiple Regressions to predict MRMI response to therapy (same explanations as Table 4a)

	$\beta$	Standard Error	Standardized $\beta$ coefficients	Partial $r$	$p$	Pearson $r$
wCST-LL	-0.489	0.209	-0.241	-0.335*	0.024	-0.195
Age	-0.079	0.049	-0.168	-0.241	0.111	-0.125
Fazekas Score	0.382	0.768	0.051	-0.076	0.621	0.001
Baseline score	-0.701	0.081	-0.740	-0.798**	0.000	-0.752*
Time	-0.133	0.058	-0.215	-0.330*	0.027	-0.369*

**Table 5.** Significant cluster from the VLSM analysis of Walk Speed response to therapy, obtained from a design including age, Fazekas score, baseline Walk Speed and time from stroke to baseline assessment as nuisance covariates (see Methods). Clusters are anatomically labelled by the Hammers and John Hopkins University white-matter label tracts (JHU) atlases (rounded % of overlap in brackets). Only overlaps  $\geq 1\%$  are listed.

	Cluster size*	Centre of mass <sup>§</sup>	p <sup>†</sup>	Hammers (anatomy)	JHU (white matter tracts)
<b>Walk Speed</b>	309	[-30,5,4]	<0.02	Insula (67) Putamen (27) Middle frontal gyrus (3)	Inferior fronto-occipital fasciculus (28) Superior longitudinal fasciculus (24) Uncinate fasciculus (14) Anterior thalamic radiation (3)

\*Cluster size in voxels (corresponds to a volume of 2.47ml); §: MNI coordinates; †: p value (p<0.05)

FWE following uncorrected threshold of p<0.005; see Methods)

## Figure Legends

**Figure 1.** Lesion overlap map from the 50 participants overlaid on a standard MNI space brain after the right-sided lesions had been flipped to the left side (see Methods), and projected onto the whole set of axial slices from the canonical normal subject T1-weighted MRI in Montreal Neurological Institute (MNI) space. The number of participants in each pixel is shown on the pseudo-colour scale on the right. The maximum number of participants with a lesion for any voxel was 24 (red colour) and involved the striato-capsular area and corona radiata.

**Figure 2.** Significant VLSM cluster (yellow) showing lesioned voxels negatively correlated with Walk Speed response to therapy, projected onto the MNI canonical T1-weighted MRI (see Fig 1 for details). Only the axial slices with significant voxels are presented (the figure above each slice is the z coordinate in mm in MNI space). Statistical significance was determined following permutation correction at  $p < 0.05$  FWE correction for multiple comparisons, and controlling for age, Fazekas score, time since stroke onset and baseline Walk Speed score as nuisance covariates in the multivariate model (see Methods). See Table 5 for coordinates, p value and anatomical location of the cluster. The canonical JHU corticospinal tract (blue) did not overlap with the cluster.

### Supplemental Figure legends

**Supplemental Figure 1:** Selected coronal, axial and sagittal sections in normalized MNI space of the canonical CST tract used in this study for wCST-LL calculations, illustrating it encompasses the CST fibers originating from the primary motor cortex leg area.

**Supplemental Figure 2:** Lesion overlap map with a minimum of 6 participants with lesion for each particular pixel (same presentation as Figure 1). The coloured area therefore represents the search volume for the VLSM analysis (see Methods).

**Supplemental Figure 3:** Power map from the lesion overlaps with the zero-thresholded corticospinal tract overlaid (blue). Note that the tract intersects close to the peak overlap. See Figure 1 for details regarding presentation. Power is represented as the probability of detecting an effect at the  $p < 0.05$  level for the distribution of 50 lesions.





Figure 1. Lesion overlap map from the 50 participants overlaid on a standard MNI space brain after the right-sided lesions had been flipped to the left side (see Methods), and projected onto the whole set of axial slices from the canonical normal subject T1-weighted MRI in Montreal Neurological Institute (MNI) space. The number of participants in each pixel is shown on the pseudo-colour scale on the right. The maximum number of participants with a lesion for any voxel was 24 (red colour) and involved the striato-capsular area and corona radiata.  
140x204mm (300 x 300 DPI)

Figure 2




Significant VLSM cluster (yellow) showing lesioned voxels negatively correlated with Walk Speed response to therapy, projected onto the MNI canonical T1-weighted MRI (see Fig 1 for details). Only the axial slices with significant voxels are presented (the figure above each slice is the z coordinate in mm in MNI space).

Statistical significance was determined following permutation correction at  $p < 0.05$  FWE correction for multiple comparisons, and controlling for age, Fazekas score, time since stroke onset and baseline Walk Speed score as nuisance covariates in the multivariate model (see Methods). See Table 5 for coordinates, p value and anatomical location of the cluster. The canonical JHU corticospinal tract (blue) did not overlap with the cluster.

90x50mm (300 x 300 DPI)


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Supplemental Figure 1




Selected coronal, axial and sagittal sections in normalized MNI space of the canonical CST tract used in this study for wCST-LL calculations, illustrating it encompasses the CST fibers originating from the primary motor cortex leg area.  
90x50mm (300 x 300 DPI)

Review



Supplemental Figure 2: Lesion overlap map with a minimum of 6 participants with lesion for each particular pixel (same presentation as Figure 1). The coloured area therefore represents the search volume for the VLSM analysis (see Methods).  
140x203mm (300 x 300 DPI)



Supplemental Figure 3: Power map from the lesion overlaps with the zero-thresholded corticospinal tract overlaid (blue). Note that the tract intersects close to the peak overlap. See Figure 1 for details regarding presentation. Power is represented as the probability of detecting an effect at the  $p < 0.05$  level for the distribution of 50 lesions.  
103x77mm (300 x 300 DPI)